afatinib d6 (Toronto Research Chemicals)
Toronto Research Chemicals is a verified supplier 
Toronto Research Chemicals manufactures this product 
91
Structured Review
Toronto Research Chemicals
afatinib d6
Afatinib D6, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/afatinib+d6/Afatinib-d6/pm36931580-50-10-15
Average 91 stars, based on 1 article reviews
Afatinib D6, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/afatinib+d6/Afatinib-d6/pm36931580-50-10-15
Average 91 stars, based on 1 article reviews
afatinib d6 - by Bioz Stars,
2026-10
91/100 stars
Images
Related Articles
other:Article Title: Pharmacokinetic Study and Tissue Distribution of Lorlatinib in Mouse Serum and Tissue Samples by Liquid Chromatography-Mass Spectrometry Article Snippet: Lorlatinib (>99.9%) was obtained from MedChem Express (USA), and Article Title: Wishful Thinking and IT Threat Avoidance: An Extension to the Technology Threat Avoidance Theory Article Snippet: In the present study, we developed and validated a rapid and simple liquid chromatography-tandem mass spectrometry (LC-MS/ MS) method for the determination of lorlatinib in mouse serum and tissue samples, and such a method was successfully applied to investigate the pharmacokinetic study and tissue distribution of lorlatinib after oral administration.. Samples were processed with methanol to precipitate protein and extract drugs, and Afatinib-d6 was used as the internal standard (IS).. For LC-MS/MS analysis, compounds were separated on a C18 column by gradient elution (0.1% of formic acid and methanol) at 0.5mL/min in the positive-ion mode withm/z 407.28 [M+H] for lorlatinib andm/z 492.10 [M+H] for IS. Article Title: Determining plasma and cerebrospinal fluid concentrations of EGFR-TKI in lung cancer patients. Article Snippet: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are commonly used to treat advanced non-small cell lung cancer (NSCLC).. A rapid and reliable method for measuring plasma and cerebrospinal fluid (CSF) concentrations of EGFR-TKIs is needed for therapeutic drug monitoring.. By using UHPLC‒MS/MS with multiple reaction monitoring mode, we developed a method for rapidly determining the plasma and CSF concentrations of gefitinib, erlotinib, afatinib, and osimertinib. Labeling:Article Title: Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry. Article Snippet: Background and aims: As numerous studies have reported the concentration-exposure relationships of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), therapeutic drug monitoring is a promising approach in lung cancer treatment, aiming to avoid treatment failure or toxicity.. A new method for the simultaneous analysis of five EGFR-TKIs (afatinib, erlotinib, gefitinib, icotinib and osimertinib) and their metabolites in human plasma samples was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS).. Materials and methods: Afatinib-d6, erlotinib-d6, OSI-420-d4, gefitinib-d6 and osimertinib-C13,d3 were used as internal standards (ISs). |